参考文献/References:
[1] Lateef DM,Xiao C,Reitman ML.Search for an endogenous bombesin-like receptor 3(BRS-3)ligand using parabiotic mice[J].PLoS One,2015,10(11):e0142637.DOI:10.1371/journal.pone.0142637.
[2] Majumdar ID,Weber HC.Biology and pharmacology of bombesin receptor subtype-3[J].Curr Opin Endocrinol Diabetes Obes,2012,19(1):3-7.DOI:10.1097/MED.0b013e32834ec77d.
[3] Yamada K,Wada E,Imaki J,et al.Hyperresponsiveness to palatable and aversive taste stimuli in genetically obese(bombesin receptor subtype-3-deficient)mice[J].Physiol Behav,1999,66(5):863-867.
[4] Matsumoto K,Iijima H.Sibutramine sensitivity assay revealed a unique phenotype of bombesin BB3 receptor-deficient mice[J].Eur J Pharmacol,2003,473(1):41-46.
[5] Sayegh AI.The role of bombesin and bombesin-related peptides in the short-term control of food intake[J].Prog Mol Biol Transl Sci,2013,114:343-370.DOI:10.1016/B978-0-12-386933-3.00010-8.
[6] Matsumoto K,Yamada K,Wada E,et al.Bombesin receptor subtype-3 modulates plasma insulin concentration[J].Peptides,2003,24(1):83-90.
[7] González N,Moreno P,Jensen RT.Bombesin receptor subtype 3 as a potential target for obesity and diabetes[J].Expert Opin Ther Targets,2015,19(9):1153-1170.DOI:10.1517/14728222.2015.1056154.
[8] Guan XM,Metzger JM,Yang L,et al.Antiobesity effect of MK-5046, a novel bombesin receptor subtype-3 agonist[J].J Pharmacol Exp Ther,2011,336(2):356-364. DOI:10.1124/jpet.110.174763.
[9] Reitman ML,Dishy V,Moreau A,et al.Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3(BRS-3)agonist, in healthy patients[J].J Clin Pharmacol,2012,52(9):1306-1316.DOI:10.1177/0091270011419854.
[10] Guan XM,Chen H,Dobbelaar PH,et al.Regulation of energy homeostasis by bombesin receptor subtype-3: selective receptor agonists for the treatment of obesity[J].Cell Metab,2010,11(2):101-112.DOI:10.1016/j.cmet.2009.12.008.
[11] Nakamichi Y,Wada E,Aoki K,et al.Functions of pancreatic beta cells and adipocytes in bombesin receptor subtype-3-deficient mice[J].Biochem Biophys Res Commun,2004,318(3):698-703.DOI:10.1016/j.bbrc.2004.04.081.
[12] Ramos-Álvarez I, Martín-Duce A, Moreno-Villegas Z,et al. Bombesin receptor subtype-3(BRS-3), a novel candidate as therapeutic molecular target in obesity and diabetes[J].Mol Cell Endocrinol,2013,367(1-2):109-115.DOI:10.1016/j.mce.2012.12.025.
[13] González N,Martín-Duce A,Martínez-Arrieta F,et al.Effect of bombesin receptor subtype-3 and its synthetic agonist on signaling, glucose transport and metabolism in myocytes from patients with obesity and type 2 diabetes[J].Int J Mol Med,2015,35(4):925-931.DOI:10.3892/ijmm.2015.2090.
[14] Feng Y,Guan XM,Li J,et al.Bombesin receptor subtype-3(BRS-3)regulates glucose-stimulated insulin secretion in pancreatic islets across multiple species[J].Endocrinology,2011,152(11):4106-4115.DOI:10.1210/en.2011-1440.
[15] Reitman ML,Dishy V,Moreau A,et al.Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3(BRS-3)agonist, in healthy patients[J].J Clin Pharmacol,2012,52(9):1306-1316.DOI:10.1177/0091270011419854.
[16] Ramos-lvarez I,Moreno-Villegas Z,Martín-Duce A,et al.Human BRS-3 receptor: functions/role in cell signaling pathways and glucose metabolism in obese or diabetic myocytes[J].Peptides,2014,51:91-99.DOI:10.1016/j.peptides.2013.11.002.
[17] Moreno P,Mantey SA,Nuche-Berenguer B,et al.Comparative pharmacology of bombesin receptor subtype-3, nonpeptide agonist MK-5046, a universal peptide agonist, and peptide antagonist Bantag-1 for human bombesin receptors[J].J Pharmacol Exp Ther,2013,347(1):100-116.DOI:10.1124/jpet.113.206896.
[18] González N,Martín-Duce A,Martínez-Arrieta F,et al.Effect of bombesin receptor subtype-3 and its synthetic agonist on signaling, glucose transport and metabolism in myocytes from patients with obesity and type 2 diabetes[J].Int J Mol Med,2015,35(4):925-931.DOI:10.3892/ijmm.2015.2090.
[19] Matsumoto K,Yamada K,Wada E,et al.Bombesin receptor subtype-3 modulates plasma insulin concentration[J].Peptides,2003,24(1):83-90.
[20] Lateef DM,Xiao C,Brychta RJ,et al.Bombesin-like receptor 3 regulates blood pressure and heart rate via a central sympathetic mechanism[J].Am J Physiol Heart Circ Physiol,2016,310(7):H891-H898.DOI:10.1152/ajpheart.00963.2015.
相似文献/References:
[1]赵紫琴,雒瑢,田凤石,等.替米沙坦对OLETF大鼠皮下和内脏脂肪组织PPARγ表达的影响[J].国际内分泌代谢杂志,2014,(06):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
Zhao Ziqin*,Luo Rong,Tian Fengshi,et al.Effects of telmisartan on expression of PPARγ in subcutaneous and visceral adipose tissue in OLETF rats[J].International Journal of Endocrinology and Metabolism,2014,(03):365.[doi:10.3760/cma.j.issn.1673-4157.2014.06.002]
[2]姚霜霜,张翼飞,张志国,等.小檗碱改善代谢性疾病的肠道相关机制[J].国际内分泌代谢杂志,2014,(06):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
Yao Shuangshuang,Zhang Yifei,Zhang Zhiguo,et al.The gut-related mechanisms of berberine in the treatment of metabolic diseases[J].International Journal of Endocrinology and Metabolism,2014,(03):386.[doi:10.3760/cma.j.issn.1673-4157.2014.06.007]
[3]曹萌 韦晓 刘超.自噬与胰岛β细胞功能及2型糖尿病[J].国际内分泌代谢杂志,2015,(01):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
Cao Meng,Wei Xiao,Liu Chao..Relationship between autophagy and islet β cells function, type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(03):53.[doi:10.3760/cma.j.issn.1673-4157.2015.01.013]
[4]刘艳 田秀标 韩颖.GLP-1受体激动剂呈葡萄糖依赖性刺激胰岛β细胞胰岛素分泌的机制[J].国际内分泌代谢杂志,2015,(01):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
Liu Yan*,Tian Xiubiao,Han Ying..Mechanism of GLP-1 receptor agonists in the stimulation of insulin secretion of islet β cell in a glucose-dependent manner[J].International Journal of Endocrinology and Metabolism,2015,(03):66.[doi:10.3760/cma.j.issn.1673-4157.2015.01.017]
[5]齐利琴,刘礼斌.GLP-1在2型糖尿病诱发的阿尔茨海默病治疗中的作用[J].国际内分泌代谢杂志,2016,36(01):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
Qi Liqin,Liu Libin..Effects of GLP-1 in the treatment of Alzheimer's disease induced by type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(03):48.[doi:10.3760/cma.j.issn.1673-4157.2016.01.012]
[6]梅稳,向光大,卢俊颜,等.GDF11对ApoE-/-糖尿病小鼠内皮依赖性
血管舒张功能的作用[J].国际内分泌代谢杂志,2016,36(02):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
Mei Wen*,Xiang Guangda,Lu Junyan,et al.Effects of GDF11 on endothelium-dependent vasodiation function of aorta in ApoE-/- diabetic mice[J].International Journal of Endocrinology and Metabolism,2016,36(03):101.[doi:10.3760/cma.j.issn.1673-4157.2016.02.007]
[7]殷俏,张云良,郭淑芹,等.视黄醇结合蛋白4、超敏C反应蛋白
与糖尿病视网膜病变的关系[J].国际内分泌代谢杂志,2016,36(03):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
Yin Qiao,Zhang Yunliang,Guo Shuqin,et al.Relationship of retinol binding protein 4 and high sensitive C-reactive protein with diabetic retinopathy[J].International Journal of Endocrinology and Metabolism,2016,36(03):149.[doi:10.3760/cma.j.issn.1673-4157.2016.03.02]
[8]王涛,张洁,祁范范,等.不同糖耐量人群血清25(OH)D3水平
及与胰岛β细胞功能的关系[J].国际内分泌代谢杂志,2016,36(04):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
Wang Tao*,Zhang Jie,Qi Fanfan,et al.Relationship between serum 25(OH)D3 level and islet β cell function in individuals with different glucose tolerance[J].International Journal of Endocrinology and Metabolism,2016,36(03):226.[doi:10.3760/cma.j.issn.1673-4157.2016.04.04]
[9]陈双双,王楚媛,孔令芳.铬与2型糖尿病[J].国际内分泌代谢杂志,2016,36(04):272.[doi:10.3760/cma.j.issn.1673-4157.2016.04.13]
Chen Shuangshuang,Wang Chuyuan,Kong Lingfang.Chromium and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2016,36(03):272.[doi:10.3760/cma.j.issn.1673-4157.2016.04.13]
[10]涂萍,许婷,段鹏,等.25-羟维生素D3补充对绝经后2型糖尿病
患者胰岛素敏感性及血糖控制的影响[J].国际内分泌代谢杂志,2016,36(05):299.[doi:10.3760/cma.j.issn.1673-4157.2016.05.04]
Tu Ping,Xu Ting,Duan Peng,et al.Influence of 25-hydroxyvitamin D3 supplement on insulin sensitivity and glucose control in postmenopausal patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2016,36(03):299.[doi:10.3760/cma.j.issn.1673-4157.2016.05.04]